Lilly-Backed TRex Bio Targets Up to $133M in U.S. IPO

“Seeking Alpha reports Eli Lilly-backed biotech TRex Bio is targeting up to one hundred thirty-three million dollars in a U.S. IPO.” — Hank Ledger, on air

On air: Hank Ledger, Vera Bullock and Dale Bearman on Market Hours
Published 11:54 AM ET, Tuesday, October 6, 2026

At a glance

First reported by Seeking Alpha: “Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPO”.
Covered on BBN on Tuesday, October 6, 2026, at 11:54 AM ET on Market Hours, by Hank Ledger, Vera Bullock and Dale Bearman.
Topics: US IPO.
BBN covered this story before: DayOne IPO Filing, Obama in Detroit, Gold Steady (October 5).

The real story

The reporting behind this segment. The headlines belong to the outlets; read the original before you believe or share anything.

Seeking AlphaEli Lilly-backed TRex Bio targets up to $133M in U.S. IPO

What BBN said about it

Hank Ledger · Lead AnchorSeeking Alpha reports Eli Lilly-backed biotech TRex Bio is targeting up to one hundred thirty-three million dollars in a U.S. IPO.
Hank Ledger · Lead AnchorSeeking Alpha's angle is that it signals continued investor appetite for therapeutic innovation. The ticker is L-L-Y-B. Details on pricing and timing were not given.
Vera Bullock · Co-AnchorHank, the market agrees.
Vera Bullock · Co-AnchorThe Nasdaq is up point eight three percent at twenty-seven thousand seven hundred four, and the S and P is up point eight five.
Hank Ledger · Lead AnchorThe VIX is at fifteen point twenty-nine, down one point four eight percent. Futures are higher too. What to watch is whether biotech demand holds.